Saraswati Sukumar
0000-0002-5656-6703
Publication & Citation Trends
Publications
0 total
Abstract 2115: Development of the cf-MMSP assay for enhanced detection of methylated cfDNA in breast cancer by liquid biopsy.
Cited by 0
Semantic Scholar
CRYβB2 is a biomarker for poor prognosis and response to CDK4/6 inhibitors in breast cancer
Cited by 0
Semantic Scholar
Abstract 1959: The potential of methylated DNA markers for accurate detection of high-risk, HPV-positive cervical lesions.
Cited by 0
Semantic Scholar
Abstract 2587: Development of a methylated gene panel for detection of cell-free, metastatic prostate cancer DNA in plasma
Cited by 0
Semantic Scholar
Discovery and technical validation of high-performance methylated DNA markers for the detection of cervical lesions at risk of malignant progression in low- and middle-income countries OA
Cited by 7
Semantic Scholar
Nanoparticle-based combination therapy enhances fulvestrant efficacy and overcomes tumor resistance in ER-positive breast cancer.
Cited by 12
Semantic Scholar
Retraction Note: HIF-1-dependent expression of angiopoietin-like 4 and L1CAM mediates vascular metastasis of hypoxic breast cancer cells to the lungs OA
Cited by 0
Semantic Scholar
In situ Injection of pH- and Temperature-Sensitive Nanomaterials Increases Chemo-Photothermal Efficacy by Alleviating the Tumor Immunosuppressive Microenvironment [Retraction] OA
Cited by 0
Semantic Scholar
Research Topics
Epigenetics and DNA Methylation
(149)
Cancer Genomics and Diagnostics
(120)
Cancer Cells and Metastasis
(52)
Cancer-related Molecular Pathways
(49)
Estrogen and related hormone effects
(46)
Affiliations
University of North Carolina at Chapel Hill
Tata Institute of Fundamental Research
University of Maryland, Baltimore
Brigham and Women's Hospital
Novartis (Switzerland)